Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Spectral on Linkedin Today

<< Previous

Bullboard Posts

Next >>

Post by TechOneon Dec 12, 2024 12:57pm

111 Views

Post# 36359260

Spectral on Linkedin Today

Research indicates that elevated endotoxin levels correlate with disease severity and patient outcomes, making EAA a valuable tool in clinical settings.

The endotoxin activity assay (EAA) has confirmed the link between systemic LPS presence and Gram-negative infections in hospitalized patients.

In the MEDIC trial, the EAA demonstrated a sensitivity of 85.3% for detecting Gram-negative infections and a negative predictive value of 98.6% for ruling them out.

Endotoxemia was also found in patients with Gram-positive infections and those without culture-positive organisms, suggesting LPS may translocate from the gut.

High levels of endotoxin (EA ≥0.6) were associated with an increased risk of severe sepsis and ICU mortality.

The EAA can help identify patients who may benefit from anti-endotoxin therapies, as seen in preliminary studies combining EAA with hemoperfusion devices.

The assay is useful in ruling out Gram-negative infections in ICU patients presenting with systemic inflammatory responses without clear infection sources.

The combination of diagnostic assays with specific therapeutic agents may enhance treatment efficacy and patient selection

https://buff.ly/3Bfc38v

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly